ArticleBMC pediatrics2026
Factors associated with short-term response after systemic corticosteroid treatment in invasively ventilated preterm infants.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the factors affecting the short-term efficacy of systemic corticosteroid (CS) therapy, focusing on pulmonary hypertension (PH) and other clinical conditions in preterm infants with evolving or established bronchopulmonary dysplasia (BPD).
methodsA retrospective review was conducted on preterm infants (< 32 weeks of gestation and/or < 1,500 g birth weight) who received systemic CS therapy for BPD. Responders were defined as infants who were extubated within 14 days and/or achieved a ≥ 60% reduction in the respiratory severity score (RSS).
resultsOf the 62 infants, 32 were classified as responders and 30 as non-responders. Non-responders had a significantly higher prevalence of PH requiring treatment (70.0% vs. 21.9%, p < 0.001) and hemodynamically significant patent ductus arteriosus (hsPDA) at treatment initiation (30.0% vs. 3.1%, p = 0.005). Responders showed a greater reduction in RSS from day 1 to day 4 (33.8% vs. 11.7%, p = 0.002). In multivariate analysis, PH requiring treatment (adjusted odds ratio [aOR]: 6.66, 95% confidence interval [CI]: 1.39-31.92, p = 0.018) and hsPDA (aOR: 12.54, 95% CI: 1.16-135.05, p = 0.037) at treatment initiation were significant predictors of non-response.
conclusionIdentifying the vascular phenotypes of BPD, including PH and hsPDA, before initiating systemic CS therapy may improve patient selection and optimize treatment outcomes. Incorporating early changes in RSS from treatment day 1 to day 4 enhanced the predictive accuracy for treatment failure and may facilitate the timely identification of non-responders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.